Neoplasms

Inclusion Criteria

- The following criteria apply to ALL patients starting the study treatment:
 -- Patients with histologically confirmed, locally advanced or metastatic solid tumors refractory to standard therapy or in whom regorafenib is considered a standard treatment.
 -- Male or  Female Caucasian patients >/= 18 years of age
 -- Women of childbearing potential and men must agree to use adequate contraception before entering the program until at least 8 weeks after the last study drug administration.
 -- Life expectancy of at leat 12 weeks
 -- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
 -- Adequate bone marrow and liver function
 -- Estimated creatinine clearance (CLcr) ≥ 30 mL/min as calculated using the Cockroft-Gault (C-G) equation.
 -- Thyroid Stimulating Hormone(TSH) within normal ranges.
 - The following inclusion criteria apply to Group A (digoxin + regorafenib) patients ONLY: 
 -- Potassium, magnesium and calcium blood levels within normal range according to the local laboratory.
 - The following inclusion criteria apply to Group B (rosuvastatin + regorafenib) patients ONLY:
 -- Signed genetic informed consent. Patients must be able to understand and willing to sign the written informed consent intended to screen for BCRP and OATP1B1 polymorphisms. 

 -

Exclusion Criteria

- For ALL patients
 - Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication.
 - Non-healing wound, skin ulcer, or bone fracture.
 - Ongoing or active infection.
 - Other anticancer treatment. 
 - Patients unable to swallow oral medications
 - For Group A (digoxin + regorafenib): 
 -- Family history of sudden cardiac death.
 - For Group B (rosuvastatin + regorafenib):
 --  Patients with porphyria. 
 -- Patients with intestinal or urinary obstructions.